(Q56240758)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

title

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

0 references

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

16

Susan M Domchek

1 reference

23 August 2018

3

Rita K Schmutzler

1 reference

23 August 2018

Ronnie Shapira-Frommer

2

object named as

Ronnie Shapira-Frommer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

author name string

Bella Kaufman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

M William Audeh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Michael Friedlander

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Gillian Mitchell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Georgeta Fried

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Salomon M Stemmer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Ayala Hubert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Ora Rosengarten

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Mariana Steiner

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Niklas Loman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Karin Bowen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

Anitra Fielding

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

language of work or name

English

0 references

publication date

3 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

23 August 2018

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

page(s)

244-250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

23 August 2018

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

7 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6057749

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25366685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25366685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2014.56.2728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25366685%20AND%20SRC:MED&resulttype=core&format=json

23 August 2018

PubMed publication ID

25366685

1 reference